Summary
Introduction
Cimetidine is one of the successes of this decade.
Its potency to lower basal and stimulated gastric acid output had been documented; it presents an effective treatment for peptic ulcer, peptic oesophagitis and the Zollinger-Ellison syndrome and it has deepened our understanding ofgastric physiology and pathophysiology.
The drug has been reported as safe and, apart from minor subjective complaints and minor elevations of serum creatinine, most of which are transient, no definitive side effects have been documented (Burland and Simkins, 1977) . Hall (1976) drew attention to the development of gynaecomastia in 2 male patients during cimetidine treatment, while Delle Fave et al. (1977) reported on elevated plasma prolactin concentrations in all of 7 patients on oral cimetidine maintenance treatment. At the time that the present investigations were started, the only definite study on cimetidine and prolactin reported a significant increase in plasma prolactin concentration after acute intravenous administration of cimetidine (Carlson and Ippoliti, 1977) . Since (Cavallini et al., 1978; Daubresse, Meunier and Ligny, 1978; Rowley-Jones, 1978) . (Tables 1-4) .
The only exception concerns FSH. FSH blood levels at 10 min after stimulation with LHRH were slightly but significantly higher at day 56 (3.38± 0.47) than at day 1 (3-00±t0.36) and day 28 (2.87± 0.40).
In the volunteers no statistically significant difference was found between the PRL values on any day.
Discussion
Prolactin shows a sleep-related circadian rhythm with one or more peaks between 2 and 5 a.m. (Rowley-Jones, 1978; Spiegel et al., 1978; Valcavi et al., 1978 During the final preparation of this manuscript, Funder and Mercer (1979) presented experimental evidence suggesting competitive binding ofcimetidine to androgen receptors which might supply some explanation for cimetidine-associated gynaecomastia.
